Vaginal cytokines do not differ between postmenopausal women with and without symptoms of vulvovaginal irritation

Menopause

Volumn 21, Issue 8, 2014, Pages 840-845

  Stute, Petra ^a   Kollmann, Zahraa ^a   Bersinger, Nick ^a   Von Wolff, Michael ^a   Thurman, Andrea R ^b   Archer, David F ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Interleukin 1A; Interleukin 6; Interleukin 8; Menopause; Tumornecrosis factor ; Vulvovaginal atrophy

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONAL THERAPY; HUMAN; MENOPAUSE; MICROSCOPY; PELVIC EXAMINATION; PH; PILOT STUDY; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; VAGINA ATROPHY; VAGINA PAIN; VAGINAL BURNING SENSATION; VAGINAL LAVAGE; VAGINAL PRURITUS; VAGINITIS; ATROPHY; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; VAGINA; VAGINA DISEASE;

ADULT; ATROPHY; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; MIDDLE AGED; POSTMENOPAUSE; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; VAGINA; VAGINAL DISEASES;

EID: 84904965142     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000179     Document Type: Article

References (40)

1. Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194-203.
2. Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17A-estradiol. Menopause 2000;7:310-317.
3. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(suppl 1):s1-s66.
4. Donders GG, Bosmans E, Dekeersmaecker A, Vereecken A, Van Bulck B, Spitz B. Pathogenesis of abnormal vaginal bacterial flora. Am J Obstet Gynecol 2000;182:872-878.
5. Fidel PL Jr, Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 1996;9:335-348.
6. Fichorova RN, Bajpai M, Chandra N, et al. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 2004;71:761-769.
7. DCruz OJ, Uckun FM. Preclinical evaluation of a dual-acting microbicidal prodrug WHI-07 in combination with vanadocene dithiocarbamate in the female reproductive tract of rabbit, pig, and cat. Toxicol Pathol 2007;35:910-927.
8. Galen BT, Martin AP, Hazrati E, et al. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis 2007;195:1332-1339.
9. Petricevic L, Unger FM, Viernstein H, Kiss H. Randomized, doubleblind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2008;141:54-57.
10. Cummins JE Jr, Doncel GF. Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety. Sex Transm Dis 2009; 36(suppl 3):S84-S91.
11. Su HI, Schreiber CA, Fay C, et al. Mucosal integrity and inflammatory markers in the female lower genital tract as potential screening tools for vaginal microbicides. Contraception 2011;84:525-532.
12. Fichorova RN. Guiding the vaginal microbicide trials with biomarkers of inflammation. J Acquir Immune Defic Syndr 2004;37(suppl 3):S184-S193.
13. Alfano M, Poli G. Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Mol Immunol 2005;42:161-182.
14. Mauck CK, Ballagh SA, Creinin MD, et al. Six-day randomized safety trial of intravaginal lime juice. J Acquir Immune Defic Syndr 2008;49: 243-250.
15. Cummins JE, Christensen L, Lennox JL, et al. Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS Res Hum Retroviruses 2006;22:788-795.
16. Spear GT, Sha BE, Saarloos MN, et al. Chemokines are present in the genital tract of HIV-seropositive and HIV-seronegative women: correlation with other immune mediators. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:454-459.
17. Garcia-Velasco JA, Arici A. Chemokines and human reproduction. Fertil Steril 1999;71:983-993.
18. Franklin RD, Kutteh WH. Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J Reprod Immunol 1999;42:93-106.
19. Fichorova RN, Lai JJ, Schwartz JL, Weiner DH, Mauck CK, Callahan MM. Baseline variation and associations between subject characteristics and five cytokine biomarkers of vaginal safety among healthy nonpregnant women in microbicide trials. Cytokine 2011;55:134-140.
20. Al-Harthi L, Wright DJ, Anderson D, et al. The impact of the ovulatory cycle on cytokine production: evaluation of systemic, cervicovaginal, and salivary compartments. J Interferon Cytokine Res 2000;20:719-724.
21. Macneill C, de Guzman G, Sousa GE, et al. Cyclic changes in the level of the innate immune molecule, surfactant protein-A, and cytokines in vaginal fluid. Am J Reprod Immunol 2012;68:244-250.
22. Africander D, Louw R, Verhoog N, Noeth D, Hapgood JP. Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract. Contraception 2011;84:423-435.
23. Dahn A, Saunders S, Hammond JA, et al. Effect of bacterial vaginosis, Lactobacillus and Premarin estrogen replacement therapy on vaginal gene expression changes. Microbes Infect 2008;10:620-627.
24. Heinemann LA, DoMinh T, Strelow F, Gerbsch S, Schnitker J, Schneider HP. The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study. Health Qual Life Outcomes 2004;2:67.
25. Bachmann GA. Vulvo-vaginal complaints. In: Lobo R, ed. Treatment of the Postmenopausal Woman. New York, NY: Raven Press; 1994:137-142.
26. Belec L, Gherardi R, Payan C, et al. Proinflammatory cytokine expression in cervicovaginal secretions of normal and HIV-infected women. Cytokine 1995;7:568-574.
27. Cauci S, Guaschino S, De Aloysio D, et al. Interrelationships of interleukin-8 with interleukin-1A and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. Mol Hum Reprod 2003;9:53-58.
28. Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9Yinduced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 2001;184:418-428.
29. Schwartz JL, Mauck C, Lai JJ, et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind phase I safety study. Contraception 2006;74:133-140.
30. Keller MJ, Guzman E, Hazrati E, et al. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS 2007;21:467-476.
31. Anderson DJ, Williams DL, Ballagh SA, et al. Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid. Am J Reprod Immunol 2009;61:121-129.
32. Bollen LJ, Blanchard K, Kilmarx PH, et al. No increase in cervicovaginal proinflammatory cytokines after Carraguard use in a placebocontrolled randomized clinical trial. J Acquir Immune Defic Syndr 2008;47:253-257.
33. Hedges SR, Barrientes F, Desmond RA, Schwebke JR. Local and systemic cytokine levels in relation to changes in vaginal flora. J Infect Dis 2006;193:556-562.
34. Nikolaitchouk N, Andersch B, Falsen E, Strombeck L, Mattsby-Baltzer I. The lower genital tract microbiota in relation to cytokine-, SLPI- and endotoxin levels: application of checkerboard DNA-DNA hybridization (CDH). APMIS 2008;116:263-277.
35. Anton G, Rid J, Mylonas I, Friese K, Weissenbacher ER. Evidence of a TH1-shift of local vaginal inflammatory response during bacterial vaginosis. Infection 2008;36:147-152.
36. Fichorova RN, Richardson-Harman N, Alfano M, et al. Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem 2008;80:4741-4751.
37. Elliott CL, Allport VC, Loudon JA, Wu GD, Bennett PR. Nuclear factor-J B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells. Mol Hum Reprod 2001;7:787-790.
38. Heinemann C, Reid G. Vaginal microbial diversity among postmenopausal women with and without hormone replacement therapy. Can J Microbiol 2005;51:777-781.
39. Sha BE, Zariffard MR, Wang QJ, et al. Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis 2005;191:25-32.
40. Cherpes TL, Meyn LA, Krohn MA, Lurie JG, Hillier SL. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis 2003;37:319-325.